Mechanistic description
Electrostatic bridging by glycans and low-abundance proteins preserves disease-relevant fibril architecture.
Mechanism / pathway
- SNCA
- neurodegeneration
Evidence for (5)
Heparan sulfate proteoglycans in alpha-synuclein aggregation and Parkinsonism.
Glycosaminoglycans modulate alpha-synuclein fibrillation kinetics.
CSF glycosaminoglycans as biomarkers of synucleinopathy.
Glycosaminoglycan-binding sites on alpha-synuclein govern aggregation and uptake.
Heparan sulfate modifications in dementia with Lewy bodies CSF.
Evidence against (1)
The mechanism remains too diffuse without isolation of a named molecular species.
Evidence matrix
Supporting
- Heparan sulfate proteoglycans in alpha-synuclein aggregation and Parkinsonism. PMID:35790300 · 2022 · Acta Neuropathol
- Glycosaminoglycans modulate alpha-synuclein fibrillation kinetics. PMID:32824376 · 2020 · Acta Neuropathol
- CSF glycosaminoglycans as biomarkers of synucleinopathy. PMID:34626424 · 2021 · Acta Neuropathol
- Glycosaminoglycan-binding sites on alpha-synuclein govern aggregation and uptake. PMID:35962883 · 2022 · Neurobiol Dis
- Heparan sulfate modifications in dementia with Lewy bodies CSF. PMID:36995304 · 2023 · Acta Neuropathol
Contradicting
- The mechanism remains too diffuse without isolation of a named molecular species.
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). Sulfated glycans and metal-binding CSF proteins brace alpha-synuclein fibril po…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-6f6f920e83
@misc{scidex_hypothesis_h6f6f920,
title = {Sulfated glycans and metal-binding CSF proteins brace alpha-synuclein fibril po…},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-6f6f920e83},
note = {SciDEX artifact hypothesis:h-6f6f920e83}
}